BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 32487753)

  • 1. Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
    Grimsey EM; Fais C; Marshall RL; Ricci V; Ciusa ML; Stone JW; Ivens A; Malloci G; Ruggerone P; Vargiu AV; Piddock LJV
    mBio; 2020 Jun; 11(3):. PubMed ID: 32487753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics Reveal Potential Natural Substrates of AcrB in Escherichia coli and Salmonella enterica Serovar Typhimurium.
    Wang-Kan X; Rodríguez-Blanco G; Southam AD; Winder CL; Dunn WB; Ivens A; Piddock LJV
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity.
    Blair JM; Bavro VN; Ricci V; Modi N; Cacciotto P; Kleinekathӧfer U; Ruggerone P; Vargiu AV; Baylay AJ; Smith HE; Brandon Y; Galloway D; Piddock LJ
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3511-6. PubMed ID: 25737552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
    Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
    Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of AcrB Efflux Function Confers Loss of Virulence on
    Wang-Kan X; Blair JMA; Chirullo B; Betts J; La Ragione RM; Ivens A; Ricci V; Opperman TJ; Piddock LJV
    mBio; 2017 Jul; 8(4):. PubMed ID: 28720734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors.
    Vargiu AV; Ruggerone P; Opperman TJ; Nguyen ST; Nikaido H
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6224-34. PubMed ID: 25114133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
    Mowla R; Wang Y; Ma S; Venter H
    Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
    Bailey AM; Paulsen IT; Piddock LJ
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3604-11. PubMed ID: 18694955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops.
    Elkins CA; Nikaido H
    J Bacteriol; 2002 Dec; 184(23):6490-8. PubMed ID: 12426336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Multidrug Efflux Inhibitors for Gram-Negative Bacteria.
    Marshall RL; Lloyd GS; Lawler AJ; Element SJ; Kaur J; Ciusa ML; Ricci V; Tschumi A; Kühne H; Alderwick LJ; Piddock LJV
    mBio; 2020 Jul; 11(4):. PubMed ID: 32665275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.
    Schuster S; Vavra M; Wirth DAN; Kern WV
    Microbiol Spectr; 2024 Feb; 12(2):e0304523. PubMed ID: 38170977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation.
    Aparna V; Dineshkumar K; Mohanalakshmi N; Velmurugan D; Hopper W
    PLoS One; 2014; 9(7):e101840. PubMed ID: 25025665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors.
    Schuster S; Kohler S; Buck A; Dambacher C; König A; Bohnert JA; Kern WV
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6870-8. PubMed ID: 25182653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
    Wang Y; Mowla R; Guo L; Ogunniyi AD; Rahman T; De Barros Lopes MA; Ma S; Venter H
    Bioorg Med Chem Lett; 2017 Feb; 27(4):733-739. PubMed ID: 28129976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2019 Garrod Lecture: MDR efflux in Gram-negative bacteria-how understanding resistance led to a new tool for drug discovery.
    Piddock LJV
    J Antimicrob Chemother; 2019 Nov; 74(11):3128-3134. PubMed ID: 31626705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of RamA, Which Regulates Production of the Multidrug Resistance Efflux Pump AcrAB-TolC, Increases Mutation Rate and Influences Drug Resistance Phenotype.
    Grimsey EM; Weston N; Ricci V; Stone JW; Piddock LJV
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps.
    Plé C; Tam HK; Vieira Da Cruz A; Compagne N; Jiménez-Castellanos JC; Müller RT; Pradel E; Foong WE; Malloci G; Ballée A; Kirchner MA; Moshfegh P; Herledan A; Herrmann A; Deprez B; Willand N; Vargiu AV; Pos KM; Flipo M; Hartkoorn RC
    Nat Commun; 2022 Jan; 13(1):115. PubMed ID: 35013254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Interactions of Carbapenem Antibiotics with the Multidrug Efflux Transporter AcrB of
    Atzori A; Malloci G; Cardamone F; Bosin A; Vargiu AV; Ruggerone P
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.
    Soparkar K; Kinana AD; Weeks JW; Morrison KD; Nikaido H; Misra R
    J Bacteriol; 2015 Oct; 197(20):3255-64. PubMed ID: 26240069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence, loss-of-function, or inhibition of Escherichia coli AcrB does not increase expression of other efflux pump genes supporting the discovery of AcrB inhibitors as antibiotic adjuvants.
    Ciusa ML; Marshall RL; Ricci V; Stone JW; Piddock LJV
    J Antimicrob Chemother; 2022 Feb; 77(3):633-640. PubMed ID: 34897478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.